Perry Herson, MD
Endocrinology · Williston Park, NYNPI 1396811725
Payments from drug & device makers
Across 1,509 payments — averaging $241.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuity Medical Inc$61K
- Boehringer Ingelheim$56K
- AstraZeneca$55K
- Mannkind Corporation$54K
- Lilly USA, LLC$47K
- Sanofi-aventis U.S. LLC$30K
- plus $60K from 41 others
What the payments were for
- Consulting fees$2,8881%
- Speaking & faculty fees$308,14885%
- Travel & lodging$12,4553%
- Food & beverage$40,11811%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$96,459
- Pogo Automatic Blood Glucose Monitoring System$60,843
- FARXIGA$51,952
- AFREZZA$38,619
- CYCLOSET$28,266
- SOLIQUA 100/33$16,751
- V-GO$12,585
- TOUJEO$10,914
- GVOKE HYPOPEN$9,710
- STEGLATRO$7,175
- FREESTYLE LIBRE 3$701
- Omnipod$605
- Yorvipath$366
- Korlym$250
- RECORLEV$225
- REZDIFFRA$141
- Qutenza$128
- Prolia$125
- Repatha$125
- MYCAPSSA$125
How this compares
$363,673 in reported general payments places this provider in the 95th percentile of 64 endocrinology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 176 | $240,791 |
| OzempicSemaglutide | 85 | $139,704 |
| AfrezzaInsulin Regular, Human | 84 | $136,811 |
| MounjaroTirzepatide | 59 | $127,004 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 105 | $118,480 |
| ProliaDenosumab | 53 | $90,731 |
| RybelsusSemaglutide | 34 | $80,466 |
| FarxigaDapagliflozin Propanediol | 47 | $64,674 |
| TrulicityDulaglutide | 22 | $55,018 |
| JanuviaSitagliptin Phosphate | 49 | $50,924 |
| TradjentaLinagliptin | 45 | $49,879 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $32,988 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $23,016 |
| Tresiba Flextouch U-100Insulin Degludec | 47 | $22,517 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 190 | $19,389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto | $56,402 | $302,240232 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,666 | $223,619132 claims |
| Lilly USA, LLCMounjaro, Trulicity | $46,668 | $182,02281 claims |
| Mannkind CorporationAfrezza | $54,130 | $136,81184 claims |
| AmgenProlia | $1,240 | $90,73153 claims |
| MerckJanuvia, Janumet, Janumet Xr | $7,649 | $84,86478 claims |
| AstraZenecaFarxiga | $54,766 | $64,67447 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $30,240 | $19,02421 claims |
| AbbVieSynthroid | $789 | $11,124157 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $605 | $7,202460 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 64 endocrinology providers in New York.
Other endocrinology in Williston Park
- Philip RabitoNew York$712K
- Olga LeonardiNew York$10K
- Isabela RomaoNew Hyde Park$10K
- Stephanie CharlesWest Nyack$10K
- Sanjay SahayGarden City$9K
- Norma QuijadaOrchard Park$8K
- Swaminathan GiridharanBrooklyn$7K
- Julia KaplunSuffern$6K
- Elia KassabBrooklyn$1K
- Lauren GoldenNew York$729
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.